EPIDEMIOLOGICAL, CLINICAL AND HUMANISTIC BURDEN AMONG ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) PATIENTS TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.127
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN3
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [21] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [22] LORLATINIB AS A FIRST-LINE TREATMENT FOR ALK plus ADVANCED NON-SMALL CELL LUNG CANCER: A COSTEFFECTIVENESS ANALYSIS IN SPAIN
    Presa, M.
    Vicente, D.
    Calles, A.
    Salinas-Ortega, L.
    Naik, J.
    Garcia, L. F.
    Soto, J.
    VALUE IN HEALTH, 2022, 25 (12) : S90 - S91
  • [23] ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK plus NON-SMALL CELL LUNG CANCER IN CHINA
    Xiao, F.
    Peng, X.
    Li, R.
    Luan, L.
    Le, H.
    Dong, P.
    VALUE IN HEALTH, 2024, 27 (12) : S99 - S99
  • [24] Characteristics, treatment patterns, and survival among ALK plus non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
    Cadranel, Jacques
    Park, Keunchil
    Arrieta, Oscar
    Pless, Miklos
    Bendaly, Edmond
    Patel, Dony
    Sasane, Medha
    Nosal, Adam
    Swallow, Elyse
    Galebach, Philip
    Kageleiry, Andrew
    Stein, Karen
    Degun, Ravi
    Zhang, Jie
    LUNG CANCER, 2016, 98 : 9 - 14
  • [25] Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
    Parisi, C.
    Benitez, J. C.
    Lecourt, H.
    Dall'Olio, F. G.
    Aldea, M.
    Blanc-Durand, F.
    Verge, V.
    Quivoron, C.
    Naltet, C.
    Abdayem, P.
    Lavaud, P.
    Ghigna, M. R.
    Loriot, Y.
    De Botton, S.
    Planchard, D.
    Barlesi, F.
    Soria, J-C.
    Ribrag, V.
    Friboulet, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S956 - S957
  • [26] Brain metastases and mortality in patients with ALK plus metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
    Uprety, Dipesh
    Abrahami, Devin
    Marcum, Zachary A.
    Li, Benjamin
    Sang, Angela
    Davis, Matthew
    Rifi, Nada
    Kelton, John M.
    Ramaswamy, Krishnan
    Sanghvi, Parag
    Bazhenova, Lyudmila
    LUNG CANCER, 2025, 201
  • [27] Non-small Cell Lung Cancer (NSCLC) ALK plus NSCLC: Lorlatinib enables sustained high systemic and intracranial Efficacy in the First Line
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [28] Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea
    Lim, Sung Hee
    Yoh, Kyung Ah
    Lee, Jong Seok
    Ahn, Myung-ju
    Kim, Yu Jung
    Kim, Se Hyun
    Zhang, Jie
    Patel, Dony
    Swallow, Elyse
    Kageleiry, Andrew
    Galebach, Philip
    Lee, Dongyeol
    Stein, Karen
    Degun, Ravi
    Park, Keunchil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E239 - E245
  • [29] A Patient-Centric, Phase II Trial of First-Line Lorlatinib&alk TKIs in China Advanced ALK plus Non-Small Cell Lung Cancer
    Lin, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S659 - S659
  • [30] ALK plus Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival
    Martin, C.
    Cardona, A.
    Arrieta, O.
    Castillo-Fernandez, O.
    Oblitas, G.
    Corrales, L.
    Lupinacci, L.
    Perez, M. A.
    Rojas, L.
    Gonzalez, L.
    Chirinos, L.
    Ortiz, C.
    Lema, M.
    Vargas, C.
    Puparelli, C.
    Carranza, H.
    Otero, J.
    Ramirez-Tirado, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1899 - S1900
12345